{"id":62483,"date":"2026-01-13T10:06:22","date_gmt":"2026-01-13T09:06:22","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/esteve-to-acquire-tersera-therapeutics-infusion-specialty-therapies-business-unit-expanding-u-s-presence\/"},"modified":"2026-01-13T10:06:22","modified_gmt":"2026-01-13T09:06:22","slug":"esteve-to-acquire-tersera-therapeutics-infusion-specialty-therapies-business-unit-expanding-u-s-presence","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/esteve-to-acquire-tersera-therapeutics-infusion-specialty-therapies-business-unit-expanding-u-s-presence\/","title":{"rendered":"ESTEVE to Acquire TerSera Therapeutics\u2019 Infusion Specialty Therapies Business Unit, Expanding U.S. Presence"},"content":{"rendered":"
\n

BARCELONA & DEERFIELD, Ill.–(BUSINESS WIRE)–ESTEVE and TerSera Therapeutics LLC announced today that they have entered into an agreement in which ESTEVE will acquire TerSera\u2019s Infusion Specialty Therapies Business Unit (IST). This strategic acquisition enables ESTEVE to expand its U.S. presence, with two highly specialized on-market assets and a dedicated team of sales, marketing and medical professionals.<\/p>\n

<\/a>
<\/a>
<\/a>
<\/a><\/p>\n

\nTerSera\u2019s IST business unit includes two specialty medications, Prialt\u00ae<\/sup> (ziconotide intrathecal infusion) and Quzyttir\u00ae<\/sup> (cetirizine hydrochloride injection). Prialt is the only FDA-approved, non-opioid agent indicated for the management of severe chronic pain in adult patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies, or intrathecal morphine.1<\/sup> Prialt is currently marketed in Europe by ESTEVE.2<\/sup> Quzyttir is the first and only injectable second-generation H1 antihistamine approved by the FDA for the treatment of acute urticaria in adults and children six months of age and older.3<\/sup><\/p>\n

\nWith this transaction, ESTEVE will obtain worldwide rights for Quzyttir in all territories (except for China) and consolidates its rights for Prialt worldwide.<\/p>\n

\nStaffan Sch\u00fcberg, ESTEVE\u2019s Chief Executive Officer stated: \u201cWe are excited to welcome the Infusion Specialty Therapies Business Unit and look forward to welcoming TerSera\u2019s talented team to ESTEVE. This acquisition perfectly aligns with our strategic vision of providing highly specialized solutions where there is a significant unmet medical need. By adding Quzyttir to our portfolio and expanding to the US market with Prialt, we not only strengthen our expertise in highly specialized therapies but also accelerate our expansion in the United States\u2014the world\u2019s largest pharmaceutical market.\u201d<\/p>\n

\n\u201cESTEVE has been our long-term partner for Prialt in Europe. Their expertise and core areas of focus make them the ideal future owner for IST,\u201d said Edward Donovan, Chief Executive Officer of TerSera. \u201cWe believe this transaction provides an excellent home for Prialt and Quzyttir to continue the strong momentum we have established with these medicines, while we sharpen our focus on our core therapeutic areas of oncology and rare disease.\u201d<\/p>\n

\nThis deal reinforces ESTEVE\u2019s growth in the United States, a growth that began with the acquisition in 2024 of a business specialized in rare and ultra-rare diseases in the areas of endocrinology and onco-endocrinology. ESTEVE\u2019s highly specialized portfolio has been further strengthened by the subsequent expansion in 2025: licensing-in for Ex US a biologic product used to treat children and adolescents from 2 to 18 years-old who suffer from severe primary insulin-like growth factor 1 deficiency4<\/sup>; an adjuvant treatment being investigated in the U.S. and considered standard of care outside of the U.S. where it is approved for high-grade resectable non-metastatic osteosarcoma in patients aged between 2 and 30 years5<\/sup> ; and a medicine that is used in adults and children above 5 years of age to treat aggressive and symptomatic medullary thyroid cancer.6<\/sup><\/p>\n

\nThe current transaction is expected to close in the first quarter of 2026, subject to regulatory clearances.<\/p>\n

\nPerella Weinberg Partners are the financial advisor to ESTEVE on this transaction, and Arnold & Porter are serving as legal counsel. Leerink Partners acted as the lead financial advisor to TerSera, and Kirkland & Ellis LLP is serving as legal counsel.<\/p>\n

\nAbout PRIALT\u00ae<\/sup> (Ziconotide Intrathecal Infusion)<\/b><\/p>\n

\nPRIALT is a non-opioid intrathecal analgesic indicated for the management of severe chronic pain in patients for whom intrathecal therapy is warranted and who are intolerant of or refractory to other treatments. Derived from a marine snail peptide, ziconotide acts as a selective N-type calcium channel blocker, interrupting pain signal transmission in the spinal cord. Ziconotide is administered via continuous intrathecal infusion and is not associated with the risk of addiction or respiratory depression commonly seen with opioid therapies.1<\/sup><\/p>\n

\nIMPORTANT SAFETY INFORMATION<\/b><\/p>\n\n\n
\n

\nWARNING: NEUROPSYCHIATRIC ADVERSE REACTIONS<\/b><\/p>\n

\n\u00a0<\/p>\n

\nPRIALT is contraindicated in patients with a preexisting history of psychosis. Severe psychiatric symptoms and neurological impairment may occur during treatment with PRIALT. Monitor all patients frequently for evidence of cognitive impairment, hallucinations, or changes in mood or consciousness. Discontinue PRIALT therapy in the event of serious neurological or psychiatric signs or symptoms.<\/b><\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nContraindications<\/b><\/p>\n

\nPRIALT is contraindicated in patients with:<\/p>\n